{"entity":{"id":"curasight","kind":"company","name":"Curasight","aka":["Curasight A/S"],"tldr":"Curasight is a Danish company developing a PET scan tracer and a matching radioactive treatment that both target uPAR, a protein found on aggressive cancers. The scan is being tested to judge how aggressive early prostate cancer is, and the treatment is in a first trial in brain tumours.","summary":"Curasight A/S is a Copenhagen radiopharmaceutical company founded in 2013, according to the company, to commercialise uPAR research from Rigshospitalet and the University of Copenhagen led by co-founder and chief scientific officer Andreas Kjær. Its theranostic platform uses one uPAR-targeting peptide ligand (AE105) for both PET imaging (uTRACE, 64Cu-DOTA-AE105) and radioligand therapy (uTREAT). The company says uTRACE has been evaluated in nine clinical studies in more than 450 patients across eight solid tumour types, and in 2023 it partnered uTRACE in prostate cancer diagnosis with Curium while keeping uTREAT. uTREAT entered a first-in-human phase 1 trial in glioblastoma in December 2025. Curasight listed on the Spotlight Stock Market in October 2020, raising about 97 million Danish kroner. Its first registered cancer trial, NCT06474806, a two-part phase 2 study of uPAR PET for non-invasive classification of ISUP grade in localised, untreated prostate cancer at Danish and German sites, was posted on ClinicalTrials.gov in June 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://curasight.com/"},{"label":"Company history","url":"https://curasight.com/about-us/history/"}],"tags":[],"related":[],"cancers":["prostate","prostate-low-risk","glioblastoma"],"sections":["radiopharma","imaging"],"technologies":["radioligand-therapy","pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06474806"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The uTREAT glioblastoma phase 1 trial was not found under Curasight's name on ClinicalTrials.gov in this scan.","The earlier uTRACE studies were academic studies at Rigshospitalet; the June 2024 date is Curasight's first registry posting as sponsor.","OnCo has no target record for uPAR (PLAUR), so no target is linked.","Company website read on 29 October 2026."],"hq":"Copenhagen","country":"DK","companyType":"radiopharma","website":"https://curasight.com/","ticker":"Spotlight: CURAS","founded":2013,"stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"source":"https://curasight.com/about-us/history/","note":"Listed on Spotlight Stock Market; raised approximately 97 million Danish kroner, as stated by the company. No USD figure given."}]},"route":"/companies/curasight/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"trial":[{"id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/"}]}}